Boris Sepesi

12.9k total citations · 2 hit papers
187 papers, 3.7k citations indexed

About

Boris Sepesi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Boris Sepesi has authored 187 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Pulmonary and Respiratory Medicine, 82 papers in Oncology and 70 papers in Surgery. Recurrent topics in Boris Sepesi's work include Lung Cancer Diagnosis and Treatment (63 papers), Lung Cancer Treatments and Mutations (57 papers) and Cancer Immunotherapy and Biomarkers (45 papers). Boris Sepesi is often cited by papers focused on Lung Cancer Diagnosis and Treatment (63 papers), Lung Cancer Treatments and Mutations (57 papers) and Cancer Immunotherapy and Biomarkers (45 papers). Boris Sepesi collaborates with scholars based in United States, Canada and Brazil. Boris Sepesi's co-authors include Stephen G. Swisher, Ara A. Vaporciyan, Wayne L. Hofstetter, David C. Rice, Reza J. Mehran, Mara B. Antonoff, Arlene M. Correa, Garrett L. Walsh, Jack A. Roth and John V. Heymach and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Boris Sepesi

173 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant Chemoimmunotherapy for NSCLC

2024 89 citations Boris Sepesi, Tina Cascone et al. profile →
LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

2023 67 citations Tina Cascone, Mark M. Awad et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Boris Sepesi

Since Specialization

Citations

This map shows the geographic impact of Boris Sepesi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boris Sepesi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boris Sepesi more than expected).

Fields of papers citing papers by Boris Sepesi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boris Sepesi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boris Sepesi. The network helps show where Boris Sepesi may publish in the future.

Co-authorship network of co-authors of Boris Sepesi

This figure shows the co-authorship network connecting the top 25 collaborators of Boris Sepesi. A scholar is included among the top collaborators of Boris Sepesi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boris Sepesi. Boris Sepesi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Survival outcomes of pulmonary metastasis‐directed local therapy in adenoid cystic carcinoma 2025 ·Cancer ·(unknown), Lei Feng, (unknown), Luana Guimarães de Sousa, Kaiwen Wang, (unknown), Quynh‐Nhu Nguyen, Adel K. El‐Naggar, Wayne L. Hofstetter, Boris Sepesi, Renata Ferrarotto	0
2	Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study 2024 ·Cancers ·Matheus Sewastjanow‐Silva, Lianchun Xiao, Graciela M. Nogueras‐González, Xuemei Wang, Wayne L. Hofstetter, Stephen G. Swisher, Reza J. Mehran, Boris Sepesi, Manoop S. Bhutani, Brian Weston, Emmanuel Coronel, Rebecca Waters, Jane E. Rogers, (unknown), L. R. Lyons, Norelle R. Reilly, James C. Yao, Jaffer A. Ajani, Mariela Blum Murphy	1
3	Early Interventional Treatment of High Output Chyle Leak After Esophagectomy is Associated With Improved Survival 2024 ·Annals of Surgery ·Nathaniel Deboever, Arlene M. Correa, Hope Feldman, (unknown), Mara B. Antonoff, Reza J. Mehran, Ravi Rajaram, David C. Rice, Jack A. Roth, Boris Sepesi, Stephen G. Swisher, Ara A. Vaporciyan, Garrett L. Walsh, Wayne L. Hofstetter	1
4	1209MO Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159 2024 ·Annals of Oncology ·Joshua E. Reuss, Cheuk Hong Leung, (unknown), Nicolas Zhou, (unknown), Apar Pataer, William N. William, Joseph H. Taube, Stephen Broderick, (unknown), David R. Jones, Don L. Gibbons, John V. Heymach, Valsamo Anagnostou, Heather Lin, J.J. Lee, Boris Sepesi, Jamie E. Chaft, (unknown), Tina Cascone	0
5	LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC breakdown → 2023 ·Annals of Oncology ·Tina Cascone, Mark M. Awad, (unknown), Jie He, Shun Lü, Boris Sepesi, Fumihiro Tanaka, Janis M. Taube, Robin Cornelissen, Libor Havel, (unknown), Luboš Petruželka, Lin Wu, J-L. Pujol, Hiroyuki Ito, C. Coronado Erdmann, Padma Sathyanarayana, S. Meadows–Shropshire, (unknown)	67
6	Disparities in early-stage lung cancer outcomes at minority-serving hospitals compared with nonminority serving hospitals 2023 ·Journal of Thoracic and Cardiovascular Surgery ·Nathaniel Deboever, Arlene M. Correa, Hope Feldman, (unknown), Wayne L. Hofstetter, Reza J. Mehran, David C. Rice, Jack A. Roth, Boris Sepesi, Stephen G. Swisher, Garrett L. Walsh, Ara A. Vaporciyan, Mara B. Antonoff, Ravi Rajaram	2
7	The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non–small cell lung cancer 2023 ·Journal of Thoracic and Cardiovascular Surgery ·Biniam Kidane, Matthew J. Bott, Jonathan Spicer, Leah M. Backhus, Jamie E. Chaft, Neel P. Chudgar, Yolonda L. Colson, Thomas A. D’Amico, Elizabeth A. David, Jay Lee, Sara Najmeh, Boris Sepesi, Catherine A. Shu, Jeffrey Yang, Steven Swanson, Brendon M. Stiles	24
8	Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer 2023 ·Annals of Oncology ·Hai T. Tran, Simon Heeke, Sheeba J. Sujit, Natalie I. Vokes, J. Zhang, Muhammad Aminu, Vincent K. Lam, Ara A. Vaporciyan, Stephen G. Swisher, Myrna C.B. Godoy, Tina Cascone, Boris Sepesi, Don L. Gibbons, Jia Wu, John V. Heymach	32
9	Phase I trial of perioperative chemotherapy plus immunotherapy in localized esophageal and gastroesophageal adenocarcinoma. 2023 ·Journal of Clinical Oncology ·Mariela A. Blum Murphy, Graciela M. Nogueras‐González, Matheus Sewastjanow‐Silva, Xuemei Wang, Wayne L. Hofstetter, Stephen G. Swisher, Reza J. Mehran, Boris Sepesi, Manoop S. Bhutani, Brian Weston, Emmanuel Coronel, Rebecca Waters, Jane E. Rogers, (unknown), L. R. Lyons, Norelle R. Reilly, James C. Yao, Jaffer A. Ajani	1
10	Circulomic variables predict pathologic staging preoperatively in treatment-naïve non-small cell lung cancer 2023 ·Journal of Thoracic Disease ·Nathaniel Deboever, (unknown), Wayne L. Hofstetter, Reza J. Mehran, Ravi Rajaram, David C. Rice, Jack A. Roth, Boris Sepesi, Stephen G. Swisher, Ara A. Vaporciyan, Garrett L. Walsh, Mara B. Antonoff	0
11	Financial Toxicity in Patients With Resected Lung Cancer 2023 ·Annals of Surgery ·Nathaniel Deboever, (unknown), Wayne L. Hofstetter, Reza J. Mehran, David C. Rice, Jack A. Roth, Boris Sepesi, Stephen G. Swisher, Ara A. Vaporciyan, Garrett L. Walsh, Mara B. Antonoff, Ravi Rajaram	13
12	Role of neoadjuvant chemoimmunotherapy for resectable NSCLC 2022 ·Nature Reviews Clinical Oncology ·Boris Sepesi, Stephen G. Swisher	4
13	OA13.01 S1619 A Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and Maintenance for Resectable Pleural Mesothelioma 2021 ·Journal of Thoracic Oncology ·Anne S. Tsao, (unknown), Jeremy Cetnar, Boris Sepesi, Daniel R. Gomez, John Wrangle, George R. Simon, Frank E. Mott, Richard D. Hall, Rafael Santana-Dávila, Marianna Koczywas, Mary W. Redman, Karen Kelly	7
14	Clinical Significance of [18F] Fluoro-2-Deoxy-d-Glucose/Computed Tomographic Avid Hilar Lymph Nodes in Esophageal Carcinoma Patients 2021 ·The Annals of Thoracic Surgery ·Hope Feldman, Jeremy J. Erasmus, Nicolas Zhou, Mara B. Antonoff, Reza J. Mehran, Ravi Rajaram, David C. Rice, Boris Sepesi, Stephen G. Swisher, Ara A. Vaporciyan, Garrett L. Walsh, Wayne L. Hofstetter, Sonia L. Betancourt Cuellar	0
15	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma 2019 ·Nature Medicine ·Sangeeta Goswami, Thomas Walle, Andrew Cornish, Sreyashi Basu, Swetha Anandhan, Irina Fernandez, Luis M. Vence, Jorge Blando, Hao Zhao, Shalini S. Yadav, Martina Ott, Ling Yuan Kong, Amy B. Heimberger, John de Groot, Boris Sepesi, Michael J. Overman, Scott Kopetz, James P. Allison, Dana Pe’er, Padmanee Sharma	251
16	Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer? 2019 ·Diseases of the Esophagus ·David B. Nelson, K. G. Mitchell, Brian Weston, Sonia L. Betancourt, Dipen M. Maru, David C. Rice, Reza J. Mehran, Boris Sepesi, Mara B. Antonoff, Garrett L. Walsh, Stephen G. Swisher, Jack A. Roth, Ara A. Vaporciyan, Mariela A. Blum, Wayne L. Hofstetter	15
17	Preoperative Heparin for Lung Cancer Resection Increases Risk of Reoperation for Bleeding 2019 ·Seminars in Thoracic and Cardiovascular Surgery ·Robert M. Van Haren, Ravi Rajaram, Arlene M. Correa, Reza J. Mehran, Mara B. Antonoff, Wayne L. Hofstetter, Boris Sepesi, Stephen G. Swisher, Ara A. Vaporciyan, Garrett L. Walsh, David C. Rice, Jack A. Roth	7
18	TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras -Mutant Mouse Lung Cancer Models 2018 ·Cancer Immunology Research ·Ismail M. Meraz, Mourad Majidi, Xiaobo Cao, Heather Lin, Lerong Li, Jing Wang, Veera Baladandayuthapani, David C. Rice, Boris Sepesi, Lin Ji, Jack A. Roth	42
19	Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis 2017 ·Journal of Clinical Oncology ·David B. Nelson, David C. Rice, Jiangong Niu, Scott M. Atay, Ara A. Vaporciyan, Mara B. Antonoff, Wayne L. Hofstetter, Garrett L. Walsh, Stephen G. Swisher, Jack A. Roth, Anne S. Tsao, Daniel R. Gomez, Sharon H. Giordano, Reza J. Mehran, Boris Sepesi	58
20	Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients 2016 ·Clinical Cancer Research ·Edwin R. Parra, Carmen Behrens, Jaime Rodriguez‐Canales, Heather Lin, Barbara Mino, Jorge Blando, Jianjun Zhang, Don L. Gibbons, John V. Heymach, Boris Sepesi, Stephen G. Swisher, Annikka Weissferdt, Neda Kalhor, Julie Izzo, Humam Kadara, César A. Moran, J. Jack Lee, Ignacio I. Wistuba	103

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact